RNXT logo

RNXT RenovoRx, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$0.94
-0.11 (-10.29%)

RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pan…

Market Cap: $45.45Mrenovorx.com

Price

No data yet.

Social Signal Score

39
5d
37
1 mentions
—
30d
43
5 mentions
—
60d
39
8 mentions
—
90d
39
9 mentions
—
news: 9

Analyst Ratings

5 analysts
Buyconsensus
Strong Buy 0Buy 4Hold 1Sell 0Strong Sell 0

Revenue

$1.07M
$0.00$355.3K$710.7K$1.07M
Mar 2020Sep 2026

Analyst Estimates

FY2025
$-0.28
$-0.31–$-0.26
2 analysts
FY2026
$-0.26
$-0.27–$-0.25
2 analysts
FY2027
$-0.09
$-0.10–$-0.08
2 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Shaun R. Bagai
Sector
Healthcare
Industry
Biotechnology
Employees
17
Beta
0.97
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
-1.69
renovorx.com